Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings include:
- DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring.
- "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of evidence for our medicines and advancing understanding of their real-world impact.
- Highlights of the upcoming presentations include:
Findings from an international, multicenter, phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment. - Results from a real-world study of treatment patterns and healthcare resource utilization among patients with schizophrenia before and after initiating ARISTADA using the ARISTADA INITIO® initiation regimen.